Marimed earnings release, August 12, 2026

Marimed Inc. (MRMD) · Form 8-K, Item 2.02 · Filed · SEC filing

MariMed Reports Second Quarter 2026 Earnings

NORWOOD, MA, August 12, 2026

- MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the second quarter ended June 30, 2026.

Financial Highlights¹

The following table summarizes the Company's consolidated financial highlights (in millions, except percentage amounts):¹

See the reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures and additional information about non-GAAP measures in the section entitled “Discussion of Non-GAAP Financial Measures” below and in the financials information included herewith.

Management Commentary

"The second quarter represented meaningful progress for MariMed. Revenue increased in both our wholesale and retail businesses sequentially and year over year, resulting in the highest quarterly revenue in our history. These results also reflect a substantial increase in sequential adjusted EBITDA and another quarter in which we generated positive cash flow from operations,” said Jon Levine, MariMed's Chief Executive Officer.

“Our stronger financial performance was driven by a continued focus on our priorities: operational discipline, product innovation and quality, customer experience and thoughtful capital allocation. Our balance sheet remains healthy, our brands keep resonating with consumers, and our operating model gives us the flexibility to respond quickly as markets and new opportunities evolve.”

“Looking ahead, we will build on this quarter’s results by continuing to implement our ‘Expand the Brand’ growth strategy, centered on building a leading cannabis consumer packaged goods company that owns top-selling national brands in the most popular categories. To achieve that goal, we will keep investing in product innovation, while broadening our depth in existing states. We will also pursue opportunities to enter new markets through capital-light strategies, including brand licensing.”

“Our innovation, brand portfolio, operating model, healthy balance sheet and tremendous team keep positioning us for long-term, sustainable value creation. We will also keep a close eye on the positive momentum behind additional Federal cannabis reform following this spring’s rescheduling of medical cannabis. The potential rescheduling of recreational cannabis, the implementation of 280E tax relief and broader banking reform are all catalysts that would improve the operating environment for our industry, and we are positioned to capitalize on these new opportunities if and when they emerge.”

Second Quarter 2026 Operational Highlights

• Wholesale revenue increased 6% sequentially

◦ MariMed’s branded products portfolio grew 70 basis points faster than the broader industry across the Company’s core markets, according to industry data sources

◦ Distribution of the Company’s branded products increased sequentially to 85% of available storefronts on a trailing 12-month basis

◦ Betty’s Eddies fruit chews remained the #1-selling edible brand across MariMed’s core states of Massachusetts, Maryland, Illinois and Delaware, and Vibations drink mix remained a top 10 brand across the same states, according to industry data sources

• Retail revenue increased 7% sequentially

◦ Revenue increased sequentially at 12 of 13 Thrive Dispensary retail locations

◦ Transactions across the retail network increased 7% sequentially

◦ Thrive Perks Loyalty Program membership increased 14% since the beginning of the year

• Adjusted gross margin held flat sequentially at 40%, a sign of stabilizing profitability

Conference Call

MariMed management will host a conference call on

Thursday, August 13, 2026 at 8:00 a.m. Eastern time, to discuss these results. The conference call may be accessed through MariMed’s Investor Relations website, or by clicking the following lin k:

Q226 MRMD Earnings Call.

Discussion of Non-GAAP Financial Measures

MariMed’s management uses several different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of its business, making operating decisions, and planning and forecasting future periods. The Company has provided in this release several non-GAAP financial measures: Non-GAAP Adjusted EBITDA and non-GAAP Adjusted EBITDA margin, Non-GAAP Gross margin, Non-GAAP Operating expenses and Non-GAAP Net income (loss), as supplements to Revenue, Gross margin, Operating expenses, Income (loss) from operations, Net income (loss) and other financial measures prepared in accordance with GAAP.

Management believes these non-GAAP financial measures are useful in reviewing and assessing the performance of the Company, and when planning and forecasting future periods, as they provide meaningful operating results by excluding the effects of expenses that are not reflective of its operating business performance. In addition, the Company’s management uses these non-GAAP financial measures to understand and compare operating results across accounting periods and for financial and operational decision-making. The presentation of these non-GAAP measures is not intended to be considered in isolation or as a substitute for the financial information prepared in accordance with GAAP.

Management believes that investors and analysts benefit from considering non-GAAP financial measures in assessing the Company’s financial results and its ongoing business, as it allows for meaningful comparisons and analysis of trends in the business. In particular, non-GAAP adjusted EBITDA is used by many investors and analysts themselves, along with other metrics, to compare financial results across accounting periods and to those of peer companies.... (truncated)nnabis industry, and therefore may not be directly comparable to similarly titled measures used by others.

Management defines non-GAAP Adjusted EBITDA as income (loss) from operations, determined in accordance with GAAP, excluding the following items:

• depreciation and amortization of property and equipment;

• amortization of acquired intangible assets;

• impairment or write-downs of acquired intangible assets;

• inventory revaluation;

• stock-based compensation;

• severance;

• legal settlements; and

• acquisition-related and other expenses.

For further information, please refer to the publicly available financial filings available on MariMed's Investor Relations website, as filed with the U.S. Securities and Exchange Commission, or as filed with the Canadian securities regulatory authorities on the SEDAR website.

About MariMed

MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including

Betty's Eddies

™,

Bubby’s Baked

™,

Vibations

™,

InHouse

™, and

Nature’s Heritage

™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.

Financial statements

Income Statement

Three months ended June 30, — The following table summarizes the Company's consolidated financial highlights (in millions, except percentage amounts):

Three months ended June 30, – 2026 – (unaudited)Three months ended June 30, – 2025 – (unaudited)Six months ended June 30, – 2026 – (unaudited)Six months ended June 30, – 2025 – (unaudited)
Revenue41.939.581.477.4
GAAP Gross margin39403940
Non-GAAP Gross margin40424042
GAAP Net loss-3.6-1.4-7.3-6.9
Non-GAAP Net loss-2.40.3-5.5-3.6
Non-GAAP Adjusted EBITDA3.94.87.57.3
Non-GAAP Adjusted EBITDA margin91299

Income Statement

Three months ended — (unaudited)

Three months ended – June 30, – 2026Three months ended – June 30, – 2025Six months ended – June 30, – 2026Six months ended – June 30, – 2025
Revenue41,92539,50681,40677,412
Cost of revenue25,70023,57949,90546,396
Gross profit16,22515,92731,50131,016
Gross margin38.740.338.740.1
Operating expenses:Personnel7,4757,39214,72914,733
Operating expenses:Marketing and promotion8477811,6121,689
Operating expenses:General and administrative6,8646,34313,75112,593
Operating expenses:Acquisition-related and other116139285251
Operating expenses:Bad debt5052565811,644
Operating expenses:Total operating expenses15,80714,91130,95830,910
Operating expenses:Income from operations4181,016543106
Interest and other (expense) income:Interest expense-2,007-1,762-3,983-3,524
Interest and other (expense) income:Interest income36257249
Interest and other (expense) income:Gain on extinguishment of debt699
Interest and other (expense) income:Other income, net1717
Interest and other (expense) income:Total interest and other expense, net-1,971-1,720-3,212-3,458
Interest and other (expense) income:Loss before income taxes-1,553-704-2,669-3,352
Interest and other (expense) income:Provision for income taxes2,0186914,6693,522
Interest and other (expense) income:Net loss-3,571-1,395-7,338-6,874
Interest and other (expense) income:Net income (loss) attributable to noncontrolling interests18-13631
Interest and other (expense) income:Net loss attributable to common stockholders-3,589-1,394-7,374-6,905
Net loss per share attributable to common stockholders:Basic-0.010-0.02-0.02
Net loss per share attributable to common stockholders:Diluted-0.010-0.02-0.02
Weighted average common shares outstanding:Basic399,597389,903398,529386,250
Weighted average common shares outstanding:Diluted399,597389,903398,529386,250

Income Statement

Three months ended — (unaudited)

Three months ended – June 30, – 2026Three months ended – June 30, – 2025Six months ended – June 30, – 2026Six months ended – June 30, – 2025
Non-GAAP Adjusted EBITDAGAAP Income from operations4181,016543106
Non-GAAP Adjusted EBITDADepreciation and amortization of property and equipment2,3312,1144,4843,921
Non-GAAP Adjusted EBITDAAmortization of acquired intangible assets7179691,5271,918
Non-GAAP Adjusted EBITDAStock-based compensation3505496751,096
Non-GAAP Adjusted EBITDASeverance1616
Non-GAAP Adjusted EBITDAAcquisition-related and other116139285251
Non-GAAP Adjusted EBITDAAdjusted EBITDA3,9484,7877,5307,292
Non-GAAP Adjusted EBITDA Margin (Non-GAAP adjusted EBITDA as a percentage of revenue)GAAP Income from operations12.60.70.1
Non-GAAP Adjusted EBITDA Margin (Non-GAAP adjusted EBITDA as a percentage of revenue)Depreciation and amortization of property and equipment5.65.35.45.1
Non-GAAP Adjusted EBITDA Margin (Non-GAAP adjusted EBITDA as a percentage of revenue)Amortization of acquired intangible assets1.72.41.92.5
Non-GAAP Adjusted EBITDA Margin (Non-GAAP adjusted EBITDA as a percentage of revenue)Stock-based compensation0.81.40.81.4
Non-GAAP Adjusted EBITDA Margin (Non-GAAP adjusted EBITDA as a percentage of revenue)Acquisition-related and other0.30.40.40.3
Non-GAAP Adjusted EBITDA Margin (Non-GAAP adjusted EBITDA as a percentage of revenue)Adjusted EBITDA margin9.412.19.29.4

Income Statement

Three months ended — (unaudited)

Three months ended – June 30, – 2026Three months ended – June 30, – 2025Six months ended – June 30, – 2026Six months ended – June 30, – 2025
Product sales - retail23,21822,33444,94543,064
Product sales - wholesale18,51417,13136,03133,917
Other revenue19341430431
Total revenue41,92539,50681,40677,412

Balance Sheet

(unaudited)

June 30, 2026December 31, 2025
Current assets:Cash, cash equivalents and restricted cash8,4378,884
Current assets:Accounts receivable, net9,3589,114
Current assets:Inventory36,67536,601
Current assets:Notes receivable, current portion9866
Current assets:Other current assets3,9543,825
Current assets:Total current assets58,43359,290
Current assets:Property and equipment, net86,41189,385
Current assets:Intangible assets, net15,68317,210
Current assets:Goodwill24,00224,002
Current assets:Notes receivable, net of current portion866
Current assets:Operating lease right-of-use assets7,6627,723
Current assets:Finance lease right-of-use assets3,2474,024
Current assets:Other assets929931
Current assets:Total assets197,233202,565
Current liabilities:Mortgages and notes payable, current portion3,4172,553

Cash Flow

Six months ended — (unaudited)

Six months ended – June 30, – 2026Six months ended – June 30, – 2025
Cash flows from operating activities:Net loss attributable to common stockholders-7,374-6,905
Cash flows from operating activities:Net income attributable to noncontrolling interests3631
Adjustments to reconcile net loss to cash provided by operating activities:Depreciation and amortization of property and equipment4,4843,921
Adjustments to reconcile net loss to cash provided by operating activities:Amortization of intangible assets1,5271,918
Adjustments to reconcile net loss to cash provided by operating activities:Stock-based compensation6751,096
Adjustments to reconcile net loss to cash provided by operating activities:Amortization of debt discount311222
Adjustments to reconcile net loss to cash provided by operating activities:Amortization of debt issuance costs3736
Adjustments to reconcile net loss to cash provided by operating activities:Payment-in-kind interest30
Adjustments to reconcile net loss to cash provided by operating activities:Bad debt expense5811,644
Adjustments to reconcile net loss to cash provided by operating activities:Obligations settled with common stock2
Adjustments to reconcile net loss to cash provided by operating activities:Loss on disposal of assets256
Adjustments to reconcile net loss to cash provided by operating activities:Gain on extinguishment of debt-699
Changes in operating assets and liabilities:Accounts receivable, net-1,0301,301
Changes in operating assets and liabilities:Deferred rents receivable12
Changes in operating assets and liabilities:Inventory-74-1,718
Changes in operating assets and liabilities:Other current assets50051
Changes in operating assets and liabilities:Other assets2-2,905
Changes in operating assets and liabilities:Accounts payable-1,439-2,713
Changes in operating assets and liabilities:Accrued expenses and other7481,607
Changes in operating assets and liabilities:Deferred revenue317184
Changes in operating assets and liabilities:Income taxes payable4,5663,520
Changes in operating assets and liabilities:Net cash provided by operating activities3,1681,590
Cash flows from investing activities:Purchases of property and equipment-671-575
Cash flows from investing activities:Business combinations, net of cash acquired, and asset purchases231
Cash flows from investing activities:Advances toward future business combinations and asset purchases-50
Cash flows from investing activities:Purchases and renewals of cannabis licenses-580-301
Cash flows from investing activities:Proceeds from notes receivable26
Cash flows from investing activities:Interest receivable on notes receivable-9
Cash flows from investing activities:Net cash used in investing activities-1,260-669
Cash flows from financing activities:Proceeds from mortgages2,000
Cash flows from financing activities:Payment of third-party debt issuance costs in connection with debt-9
Cash flows from financing activities:Principal payments of mortgages-805-741

Cash Flow

Six months ended — (unaudited)

Six months ended – June 30, – 2026Six months ended – June 30, – 2025
Repayment and retirement of mortgages-689
Principal payments of promissory notes-591-1,919
Principal payments of finance leases-879-626
Distributions-80-81
Net cash used in financing activities-2,355-2,065
Net decrease in cash and cash equivalents-447-1,144
Cash and equivalents, beginning of year8,8847,282
Cash and cash equivalents, end of period8,4376,138
Full release

Important Caution Regarding Forward-Looking Statements

The information in this release contains “forward-looking” statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, which are subject to several risks and uncertainties.

All statements other than statements of historical facts contained in this release, including without limitation statements regarding projected financial results for 2026, including anticipated openings of dispensaries and facilities, timing of regulatory approvals, plans and objectives of management for future operations, are forward-looking statements.

Without limiting the foregoing, the words “anticipates”, “believes”, “estimates”, “expects”, “expectations”, “intends”, “may”, “plans”, and other similar language, whether in the negative or affirmative, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements are based on our current beliefs and assumptions regarding our business, timing of regulatory approvals, the ability to obtain new licenses, business prospects and strategic growth plan, and other future conditions.

Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict.

Our actual results may differ materially from those contemplated in these forward-looking statements due to various risks, uncertainties, and other important factors, including, among others, reductions in customer spending, our ability to recruit and retain key personnel, and disruptions from the integration efforts of acquired companies.

These factors are not intended to be an all-encompassing list of risks and uncertainties that may affect our business and results of operations.

These statements are not a guarantee of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company’s services and products, changes in the law and its enforcement, and changes in the economic environment.

Additional information regarding these and other factors can be found in our reports filed with the U.S. Securities and Exchange Commission.

In providing these forward-looking statements, the Company expressly disclaims any obligation to update these statements publicly or otherwise, whether as a result of new information, future events or otherwise, except as required by law.

All trademarks and service marks are the property of their respective owners.

Neither the CSE nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.

For More Information Contact:

Howard Schacter, Chief Communications Officer

Email: hschacter@marimedinc.com

Phone: (781) 277-0007

# # #

MariMed Inc.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

MariMed Inc.

Condensed Consolidated Statements of Operations

(in thousands, except percentages and per share amounts)

(unaudited)

MariMed Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

MariMed Inc.

Reconciliation of Non-GAAP and GAAP Financial Measures

(in thousands, except percentages)

(unaudited)

MariMed Inc.

Supplemental Information

Revenue Components

(in thousands)

(unaudited)

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.